In Vitro Assessment of Injectable Bone Marrow Aspirate Concentrates Compared to Injectable Platelet-Rich Fibrin.

IF 4.4 4区医学 Q2 CELL & TISSUE ENGINEERING

Tissue engineering and regenerative medicine Pub Date : 2024-11-04 DOI:10.1007/s13770-024-00677-7

Masako Fujioka-Kobayashi, Masateru Koyanagi, Ryo Inada, Ayako Miyasaka, Takafumi Satomi

{"title":"In Vitro Assessment of Injectable Bone Marrow Aspirate Concentrates Compared to Injectable Platelet-Rich Fibrin.","authors":"Masako Fujioka-Kobayashi, Masateru Koyanagi, Ryo Inada, Ayako Miyasaka, Takafumi Satomi","doi":"10.1007/s13770-024-00677-7","DOIUrl":null,"url":null,"abstract":"Background: Injectable platelet-rich fibrin (iPRF), a liquid form of PRF that is prepared from peripheral blood without anticoagulants, promotes tissue wound healing and regeneration. The present study focused on iPRF-like bone marrow aspirate concentrate (iBMAC) prepared without anticoagulant, and the regenerative potential of iPRF and iBMAC was compared in vitro.Methods: iPRF and iBMAC were prepared from the same New Zealand white rabbits. The cytocompatibility and regenerative potential of each concentrate were evaluated using primary rabbit gingival fibroblasts and osteoblasts.Results: Both gingival fibroblasts and osteoblasts treated with each concentrate exhibited excellent cell viability. Interestingly, compared to cells treated with iPRF, cells treated with iBMAC demonstrated significantly greater migration potential. Furthermore, higher mRNA levels of transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and collagen I (COL1) were observed in gingival fibroblasts treated with iBMAC than in those treated with iPRF. Compared with osteoblasts treated with iPRF, osteoblasts treated with iBMAC exhibited greater differentiation potential, as indicated by increased osteocalcin (OCN) expression and mineralization capability.Conclusion: The results of the in vitro study suggest that, compared with iPRF, iBMAC may promote wound healing and bone regeneration more effectively. However, further preclinical and clinical studies are needed to confirm the regenerative potential of iBMAC in the body.","PeriodicalId":23126,"journal":{"name":"Tissue engineering and regenerative medicine","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue engineering and regenerative medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13770-024-00677-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Injectable platelet-rich fibrin (iPRF), a liquid form of PRF that is prepared from peripheral blood without anticoagulants, promotes tissue wound healing and regeneration. The present study focused on iPRF-like bone marrow aspirate concentrate (iBMAC) prepared without anticoagulant, and the regenerative potential of iPRF and iBMAC was compared in vitro.

Methods: iPRF and iBMAC were prepared from the same New Zealand white rabbits. The cytocompatibility and regenerative potential of each concentrate were evaluated using primary rabbit gingival fibroblasts and osteoblasts.

Results: Both gingival fibroblasts and osteoblasts treated with each concentrate exhibited excellent cell viability. Interestingly, compared to cells treated with iPRF, cells treated with iBMAC demonstrated significantly greater migration potential. Furthermore, higher mRNA levels of transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and collagen I (COL1) were observed in gingival fibroblasts treated with iBMAC than in those treated with iPRF. Compared with osteoblasts treated with iPRF, osteoblasts treated with iBMAC exhibited greater differentiation potential, as indicated by increased osteocalcin (OCN) expression and mineralization capability.

Conclusion: The results of the in vitro study suggest that, compared with iPRF, iBMAC may promote wound healing and bone regeneration more effectively. However, further preclinical and clinical studies are needed to confirm the regenerative potential of iBMAC in the body.

查看原文本刊更多论文

注射用骨髓吸出物浓缩物与注射用富血小板纤维蛋白的体外评估比较。

背景：注射用富血小板纤维蛋白（iPRF）是一种液态富血小板纤维蛋白，由外周血制备而成，不含抗凝剂，可促进组织伤口愈合和再生。本研究重点关注不含抗凝剂的类 iPRF 骨髓抽吸物浓缩液（iBMAC），并在体外比较了 iPRF 和 iBMAC 的再生潜力。方法：iPRF 和 iBMAC 由相同的新西兰白兔制备，使用原代兔牙龈成纤维细胞和成骨细胞评估了每种浓缩物的细胞相容性和再生潜力：结果：用每种浓缩物处理的牙龈成纤维细胞和成骨细胞都表现出极佳的细胞活力。有趣的是，与用 iPRF 处理过的细胞相比，用 iBMAC 处理过的细胞具有明显更高的迁移潜力。此外，用 iBMAC 处理的牙龈成纤维细胞的转化生长因子-β（TGF-β）、血管内皮生长因子（VEGF）和胶原蛋白 I（COL1）的 mRNA 水平高于用 iPRF 处理的细胞。与用 iPRF 处理的成骨细胞相比，用 iBMAC 处理的成骨细胞表现出更大的分化潜力，这体现在骨钙素（OCN）表达和矿化能力的提高上：体外研究结果表明，与 iPRF 相比，iBMAC 可更有效地促进伤口愈合和骨再生。然而，要证实 iBMAC 在体内的再生潜力，还需要进一步的临床前和临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tissue engineering and regenerative medicine CELL & TISSUE ENGINEERING-ENGINEERING, BIOMEDICAL

CiteScore

6.80

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Tissue Engineering and Regenerative Medicine (Tissue Eng Regen Med, TERM), the official journal of the Korean Tissue Engineering and Regenerative Medicine Society, is a publication dedicated to providing research- based solutions to issues related to human diseases. This journal publishes articles that report substantial information and original findings on tissue engineering, medical biomaterials, cells therapy, stem cell biology and regenerative medicine.